GlaxoSmithKline

GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the following segments: Pharmaceuticals; Pharmaceuticals R&D; Vaccines and Consumer Healthcare. The Pharmaceuticals segment focuses on developing medicines in respiratory and infectious diseases, oncology, and immuno-inflammation. The Pharmaceuticals R&D segment focuses on science related to the immune system, the use of human genetics and advanced technologies, and is driven by the multiplier effect of Science x Technology x Culture. The Vaccines segment produces pediatric and adult vaccines to prevent a range of infectious diseases including, hepatitis A and B, diphtheria, tetanus and whooping cough, measles, mumps and rubella, polio, typhoid, influenza, and bacterial meningitis. The Consumer Healthcare segment develops and markets brands in the oral health, pain relief, respiratory, nutrition and gastro intestinal, and skin health categories. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

GSK plc (LSE/NYSE: GSK) announced that it has entered into a definitive agreement to buy Affinivax. These are the details.

Why GSK (GSK) Is Buying Affinivax For Over $2 Billion

GSK PLC said Tuesday that it has agreed to buy clinical-stage biopharmaceutical company Affinivax, Inc. for up to $3.3 billion.

GSK to pay up to $3.3 billion for biopharma Affinivax

The U.K. drugmaker will make an upfront payment of $2.1 billion for Affinivax and up to $1.2 billion in potential development milestones.

GSK to Buy U.S. Biotech Affinivax in $3.3 Billion Deal

GlaxoSmithKline PLC (LSE:GSK) is to bolster its vaccine pipeline in a deal worth up to US$3.3bn. It is acquiring Affinivax Inc, which gives it access to a technology being developed to treat pneumococcal diseases such as pneumonia, meningitis and bloodstream infections.

GlaxoSmithKline bolsters its vaccines R&D pipeline with US$3.3bn swoop for American drug developer

British drugmaker GSK said on Tuesday it would pay up to $3.3 billion to acquire privately held biopharmaceutical firm Affinivax, as it seeks to bolster its vaccine pipeline.

Britain's GSK to buy Affinivax in $3.3 billion deal

AbbVie

With healthcare costs rising in the U.S., it seems as if the new drugs will have to follow suit. Big.

Two large-cap pharmaceutical stocks with a solid dividend yield

GlaxoSmithKline PLC (LSE:GSK)'s cervical cancer drug has been approved as a two-dose vaccine as protection against two forms of the human papillomavirus that can cause the disease. The country's National Medical Products Administration has given the green light for Cervarix to be given to girls aged nine to 14.

GlaxoSmithKline's cervical cancer drug wins Chinese approval

GlaxoSmithKline plc (NYSE:GSK ) UBS Global Healthcare Conference Call May 24, 2022 9:15 AM ET Company Participants Kimberly Smith - Head of Global Research & Medical Strategy Conference Call Participants Laura Sutcliffe - UBS Laura Sutcliffe All right. Good morning, everyone.

GlaxoSmithKline plc (GSK) Management Presents at UBS Global Healthcare Conference (Transcript)

GlaxoSmithKline PLC (LSE:GSK) has averted strikes at its UK manufacturing plants with a salary increase that trade unions have accepted. Trade union Unite said a 10.5% pay offer has been accepted, though GSK said the offer was a backdated 4.5% increase to base salary, as well as a one-off special award to all GSK employees of one week's pay.

GSK hikes factory workers pay after union calls out derisory offer

Eli Lilly

Merck

Novo Nordisk

Drug/biotech companies are likely to see significant advances in innovation in 2022. In the Large-Cap Pharmaceuticals industry, Eli Lilly (LLY), Novo Nordisk (NVO), Merck (MRK) and Glaxo (GSK) are worth retaining in your portfolio.

4 Large Drug Stocks to Watch as the Industry Recovers

It feels a little after the Lord Mayor's show, but Deutsche Bank believes it stumbled over a reason to buy shares in GlaxoSmithKline PLC (LSE:GSK), which have advanced 26% already over the last year. So, anyway, in its note on Thursday, DB homes on the vaccines business, which it thinks has the potential to deliver the long-term growth analysts and investors reckon is missing from the GSK story.

GlaxoSmithKline: What's the difference between a 'buy idea' and neutral recommendation?

The British drugmaker recently announced that it agreed to acquire a late-stage biopharmaceutical company.

Was This Acquisition a Smart Move for GlaxoSmithKline?

GlaxoSmithKline has moved into pole position in the race for an RSV vaccine, believes broker Berenberg, underpinning its view that the pharma giant is a buy. Data on Pfizer's rival RSV jab has been delayed due to an expansion in the numbers being enrolled and with Glaxo targeting approval and reimbursement in the first half of 2023, it is now ahead in the race believes the broker.

GlaxoSmithKline's RSV jab progress prompts upgrade

Its late-stage pipeline is heavily weighted toward pandemic treatments.

Why GSK May Have Bet Too Big on a Pandemic Pipeline

Bristol-Myers

CVS Health

Moderna

Pfizer

Should investors' be looking at these health care stocks this earnings season?

5 Health Care Stocks For Your May 2022 Watchlist

Sierra Oncology

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Sierra Oncology, Inc (NasdaqGM: SRRA) to GlaxoSmithKline plc (NYSE: GSK). Under the terms of the proposed transaction, shareholders of Sierra will receive only $55.00 in cash for each share of Sierra that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequa

SIERRA ONCOLOGY INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Sierra Oncology, Inc - SRRA

In partnership with the actress and caregiver, the brand kicks off CareWalks, a pledge to caregivers across the country that offers resources and encourages movement through a new video series, a charitable donation and more WARREN, N.J. , May 4, 2022 /PRNewswire/ -- 1 in 5 Americans provide care to family members or loved ones,1 a task that's inherently connected with physical pain.

Voltaren Teams Up with Actress Jennie Garth to Support Caregivers Nationwide

CEDARHURST, N.Y.--(BUSINESS WIRE)--Kuznicki Law PLLC is investigating the proposed sale of Sierra Oncology, Inc (NasdaqGM: SRRA) to GlaxoSmithKline plc (NYSE: GSK). Under the terms of the proposed transaction, shareholders of Sierra will receive only $55.00 in cash for each share of Sierra that they own. If you would like to discuss your legal rights regarding the proposed sale, you may, without obligation or cost to you, contact us toll free at 833-938-0905, via email (dk@kclasslaw.com), or vi

SIERRA ONCOLOGY INVESTOR ALERT - Kuznicki Law PLLC Investigates Proposed Sale of Sierra Oncology, Inc - SRRA

GSK delivered a stellar result for 1Q22, with turnover increasing 32% YOY (32% YOY constant exchange rate or CER) to £9.8 billion (10.5% vs. consensus).

GlaxoSmithKline Reports Robust 1Q22 Earnings; Beats Street Estimates

Reckitt Benckiser Group PLC

Unilever

Reckitt Benckiser Group PLC (LSE:RKT, ETR:3RB) quarterly results on Friday may have a few pick-me-ups for investors, with numbers from the Strepsils and Nurofen maker also given context from rivals Unilever and GlaxoSmithKline earlier in the week. Top shelf of the bathroom cabinet in the news is likely to be potential news on RB's infant nutrition business, where reports emerged this week that a sale process has been kicked off.

Reckitt set up to beat Unilever, GSK with potential demerger news and bumper flu season

GlaxoSmithKline Plc's (NYSE: GSK) Q1 turnover reached £9.78 billion, up 32% Y/Y on actual exchange rate AER and constant exchange rate CER basis. Specialty Medicines turnover was £3.13 billion, up 98% AER, 97% CER (+16% AER, 15% CER excluding Xevudy), driven by consistent.

GlaxoSmithKline Clocks 32% Topline Growth Buoyed By COVID-19 Therapy, Shingrix Vaccine

Glaxo's (GSK) revenues benefit from the strong growth in sales across all categories along with additional sales from its COVID-19 antibody drug, Xevudy.

Glaxo's (GSK) Q1 Earnings Top, Xevudy Adds $1.7B in Sales

GlaxoSmithKline plc (NYSE:GSK ) Q1 2022 Results Conference Call April 27, 2022 7:00 AM ET Company Participants Nick Stone - Head of Global Investor Relations Emma Walmsley - Chief Executive Officer Iain Mackay - Chief Financial Officer Deborah Waterhouse - Chief Executive Officer, ViiV Healthcare Brian McNamara - Chief Executive Officer, GSK Consumer Health Luke Miels - Chief Commercial Officer Roger Connor - President, Vaccine and Global Health Hal Barron - Chief Scientific Officer Conference Call Participants Graham Parry - Bank of America Merrill Lynch James Gordon - JPMorgan Chase & Co Laura Sutcliffe - UBS Investment Bank Timothy Anderson - Wolfe Research, LLC Kerry Holford - Joh. Berenberg, Gossler& Co. KG Peter Welford - Jefferies LLC Iain Simpson - Barclays Mark Purcell - Morgan Stanley Simon Baker - Redburn Operator Good afternoon, ladies and gentlemen, and welcome to the Analyst Call for the GSK First Quarter 2022 Results.

GlaxoSmithKline plc (GSK) CEO Emma Walmsley on Q1 2022 Results - Earnings Call Transcript

GlaxoSmithKline (GSK) is getting ready to launch its consumer health spinoff with Pfizer this summer, the company said in its first-quarter earnings report Wednesday (April 27). The company first announced plans for the division — now dubbed “Haleon” — last year.

GSK, Pfizer Consumer Health Spinoff Set to Launch in July

Shares of GlaxoSmithKline plc (LON: GSK) are up 3.0% on Wednesday after the pharmaceutical giant reported better-than-expected Q1 results on strong COVID-19 vaccine sales. GSK Q1 financial highlights At £9.80 billion ($12.3 billion), revenue was up 32% year-over-year.

News for GlaxoSmithKline Stock (GSK)